{"id":33414,"date":"2025-05-14T15:13:54","date_gmt":"2025-05-14T07:13:54","guid":{"rendered":"https:\/\/flcube.com\/?p=33414"},"modified":"2025-05-14T15:13:54","modified_gmt":"2025-05-14T07:13:54","slug":"innocare-pharma-reports-129-92-revenue-surge-in-q1-2025-turns-profitable","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33414","title":{"rendered":"InnoCare Pharma Reports 129.92% Revenue Surge in Q1 2025, Turns Profitable"},"content":{"rendered":"\n<p>Beijing-based biotech InnoCare Pharma (<a href=\"https:\/\/www.google.com\/finance\/quote\/9969:HKG\">HKG: 9969<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688428:SHA\">SHA: 688428<\/a>) released its Q1 2025 financial report, recording revenues of RMB 381 million (USD 52.8 million), marking a 129.92% year-on-year (YOY) increase. The company achieved a net profit of RMB 14 million (USD 1.94 million), marking a turnaround from loss to profitability. As of the end of the reporting period, InnoCare held RMB 7.778 billion (USD 1.1 billion) in cash and cash equivalents, underscoring its strong liquidity position.<\/p>\n\n\n\n<p><strong>Revenue Growth Drivers<\/strong><br>The significant revenue growth was primarily driven by sustained sales increases from its core product, the BTK inhibitor orelabrutinib, and an upfront payment from a licensing agreement with Prolium Bioscience Inc. In Q1 2025, orelabrutinib generated sales of RMB 311 million (USD 43 million), representing an 89.22% YOY increase. The drug received additional approval in April 2025 as a first-line treatment for adults with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL), which is expected to further accelerate sales growth.<\/p>\n\n\n\n<p><strong>Licensing Agreement Details<\/strong><br>In January 2025, InnoCare, in collaboration with Keymed Biosciences Inc. (2162.HK) and their joint venture, entered into a licensing agreement with Prolium. The agreement grants Prolium the rights to develop and commercialize the CD20\u00d7CD3 bispecific antibody CM355 (ICP-B02). The total potential deal value could reach up to USD 520 million.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/688428_20250514_BXO6.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688428_20250514_BXO6.\"><\/object><a id=\"wp-block-file--media-76de99c7-b4ca-40dd-8d5f-7cfcee359b3d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/688428_20250514_BXO6.pdf\">688428_20250514_BXO6<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/688428_20250514_BXO6.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-76de99c7-b4ca-40dd-8d5f-7cfcee359b3d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) released its Q1 2025 financial report, recording&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33416,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,919,327,920],"class_list":["post-33414","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-hkg-9969","tag-innocare-pharma","tag-sha-688428"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>InnoCare Pharma Reports 129.92% Revenue Surge in Q1 2025, Turns Profitable - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) released its Q1 2025 financial report, recording revenues of RMB 381 million (USD 52.8 million), marking a 129.92% year-on-year (YOY) increase. The company achieved a net profit of RMB 14 million (USD 1.94 million), marking a turnaround from loss to profitability. As of the end of the reporting period, InnoCare held RMB 7.778 billion (USD 1.1 billion) in cash and cash equivalents, underscoring its strong liquidity position.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33414\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InnoCare Pharma Reports 129.92% Revenue Surge in Q1 2025, Turns Profitable\" \/>\n<meta property=\"og:description\" content=\"Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) released its Q1 2025 financial report, recording revenues of RMB 381 million (USD 52.8 million), marking a 129.92% year-on-year (YOY) increase. The company achieved a net profit of RMB 14 million (USD 1.94 million), marking a turnaround from loss to profitability. As of the end of the reporting period, InnoCare held RMB 7.778 billion (USD 1.1 billion) in cash and cash equivalents, underscoring its strong liquidity position.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33414\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-14T07:13:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1412.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33414#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33414\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"InnoCare Pharma Reports 129.92% Revenue Surge in Q1 2025, Turns Profitable\",\"datePublished\":\"2025-05-14T07:13:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33414\"},\"wordCount\":210,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33414#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1412.webp\",\"keywords\":[\"Finanical Reports\",\"HKG: 9969\",\"InnoCare Pharma\",\"SHA: 688428\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33414#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33414\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33414\",\"name\":\"InnoCare Pharma Reports 129.92% Revenue Surge in Q1 2025, Turns Profitable - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33414#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33414#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1412.webp\",\"datePublished\":\"2025-05-14T07:13:54+00:00\",\"description\":\"Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) released its Q1 2025 financial report, recording revenues of RMB 381 million (USD 52.8 million), marking a 129.92% year-on-year (YOY) increase. The company achieved a net profit of RMB 14 million (USD 1.94 million), marking a turnaround from loss to profitability. As of the end of the reporting period, InnoCare held RMB 7.778 billion (USD 1.1 billion) in cash and cash equivalents, underscoring its strong liquidity position.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33414#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33414\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33414#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1412.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1412.webp\",\"width\":1080,\"height\":608,\"caption\":\"InnoCare Pharma Reports 129.92% Revenue Surge in Q1 2025, Turns Profitable\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33414#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InnoCare Pharma Reports 129.92% Revenue Surge in Q1 2025, Turns Profitable\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"InnoCare Pharma Reports 129.92% Revenue Surge in Q1 2025, Turns Profitable - Insight, China&#039;s Pharmaceutical Industry","description":"Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) released its Q1 2025 financial report, recording revenues of RMB 381 million (USD 52.8 million), marking a 129.92% year-on-year (YOY) increase. The company achieved a net profit of RMB 14 million (USD 1.94 million), marking a turnaround from loss to profitability. As of the end of the reporting period, InnoCare held RMB 7.778 billion (USD 1.1 billion) in cash and cash equivalents, underscoring its strong liquidity position.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33414","og_locale":"en_US","og_type":"article","og_title":"InnoCare Pharma Reports 129.92% Revenue Surge in Q1 2025, Turns Profitable","og_description":"Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) released its Q1 2025 financial report, recording revenues of RMB 381 million (USD 52.8 million), marking a 129.92% year-on-year (YOY) increase. The company achieved a net profit of RMB 14 million (USD 1.94 million), marking a turnaround from loss to profitability. As of the end of the reporting period, InnoCare held RMB 7.778 billion (USD 1.1 billion) in cash and cash equivalents, underscoring its strong liquidity position.","og_url":"https:\/\/flcube.com\/?p=33414","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-14T07:13:54+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1412.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33414#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33414"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"InnoCare Pharma Reports 129.92% Revenue Surge in Q1 2025, Turns Profitable","datePublished":"2025-05-14T07:13:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33414"},"wordCount":210,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33414#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1412.webp","keywords":["Finanical Reports","HKG: 9969","InnoCare Pharma","SHA: 688428"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33414#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33414","url":"https:\/\/flcube.com\/?p=33414","name":"InnoCare Pharma Reports 129.92% Revenue Surge in Q1 2025, Turns Profitable - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33414#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33414#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1412.webp","datePublished":"2025-05-14T07:13:54+00:00","description":"Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) released its Q1 2025 financial report, recording revenues of RMB 381 million (USD 52.8 million), marking a 129.92% year-on-year (YOY) increase. The company achieved a net profit of RMB 14 million (USD 1.94 million), marking a turnaround from loss to profitability. As of the end of the reporting period, InnoCare held RMB 7.778 billion (USD 1.1 billion) in cash and cash equivalents, underscoring its strong liquidity position.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33414#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33414"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33414#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1412.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1412.webp","width":1080,"height":608,"caption":"InnoCare Pharma Reports 129.92% Revenue Surge in Q1 2025, Turns Profitable"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33414#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"InnoCare Pharma Reports 129.92% Revenue Surge in Q1 2025, Turns Profitable"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1412.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33414","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33414"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33414\/revisions"}],"predecessor-version":[{"id":33417,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33414\/revisions\/33417"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33416"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33414"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33414"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33414"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}